65,437 trials
Oropharyngeal Squamous Cell Cancer
Primary: Median Change in Quality of Life (QOL) From Baseline to 12 Months Post Treatment — -4.2; 0; 6.3; 10.7 score on a scale
Hepatic Disease · Renal Disease
Primary: Absence of Hematoma Formation — 30 participants
Thermal Burns
Primary: Primary Endpoint: Number of Participants With Complete Eschar Removal. — 70; 1 Participants — p=<0.0001
Nonproliferative Diabetic Retinopathy
Primary: Percentage of Subjects With an Improvement in Study Eye Severity of Diabetic Retinopathy (DR) (ETDRS DR Severity Score or DRSS) of ≥ 2 Steps — 0; 5; 2 eyes — p=0.495
Colorectal Cancer
Primary: Rectal Tissue Putrescine Reduction — 17 Participants
Healthy
Primary: Change in Putamen Node Strength — 0.73; -0.42 unitless
Malignant Diseases · Non-malignant Diseases
Primary: Number of Patients With Severe (Grade III/IV) Acute Graft vs Host Disease (GVHD) — 0 Participants
Breast Cancer
Primary: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer…
Mesial Temporal Lobe Epilepsy
Primary: Safety and Tolerability of Low Frequency Stimulation of the Fornix With Regards to Memory Function — 0; 0 Participants
Human Immunodeficiency Virus
Primary: Grade 3 and Serious Adverse Events — 0 Participants
Post-ERCP Acute Pancreatitis
Primary: Sensitivity and Specificity of Urine Trypsinogen-2 Dipstick Testing for the Diagnosis of Post-ERCP Pancreatitis — 11.1; 91; 4.4; 96.5 percentage of participants
Postoperative Pain
Primary: Mean Area Under the Curve (AUC) of the NRS-A (Windowed Worst Observation Carried Forward) Pain Intensity Scores — 278.36; 288.23; 126.93 pain intensity score*hr
Desmoid Tumor
Primary: Immunohistochemical Immunoreactive Score Results After 4 Weeks of Sirolimus Compared to Control Specimens — 5.22; 7.44; 4.47; 9.39 score on a scale — p=0.63
Solid Tumor
Primary: Number of Participants With Adverse Events (AEs). — 8; 6; 12; 7 Participants
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Percentage of Participants Who Achieved Adequate Control of Intravascular Hemolysis — 75.0 Percentage of Participants